Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022-2023 and 2023-2024 seasons.

Mahrukh Imran¹, Benjamin Chastek², Tim Bancroft³, Noah Webb⁴, Stephen I Pelton⁵, Mendel D M Haag⁶, Ian McGovern⁷

¹CSL Seqirus, Kirkland, QC, Canada. Electronic address: mahrukh.imran@seqirus.com.

²Optum, Eden Prairie, MN, USA. Electronic address: benjamin.chastek@optum.com.

³Optum, Eden Prairie, MN, USA. Electronic address: timothy.bancroft@optum.com.

⁴Optum, Eden Prairie, MN, USA. Electronic address: noah.webb@optum.com.

⁵Boston Medical Center, Boston, MA, USA. Electronic address: spelton@bu.edu.

⁶CSL Seqirus, Amsterdam, The Netherlands. Electronic address: mendel.haag@seqirus.com.

⁷CSL Seqirus, Waltham, MA, USA. Electronic address: ian.mcgovern@seqirus.com.

PubMed DOI

Abstract

OBJECTIVES: Evaluate relative vaccine effectiveness (rVE) of adjuvanted quadrivalent influenza vaccine (aQIV) versus high-dose QIV (HD-QIV) in preventing test-confirmed influenza during 2023-2024 in any setting and emergency department (ED)/hospitalization settings, as well as in preventing hospitalizations in overall and high-risk older adults in a pooled analysis from 2022-2024. METHODS: This r…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.